Search
XL999
go.drugbank.com/drugs/DB05014InvestigationalXL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models. … XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response.
NOV-002
go.drugbank.com/drugs/DB05393InvestigationalNOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. … NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim.
Taliglucerase alfa
go.drugbank.com/drugs/DB08876ApprovedIt was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Levoglucose
go.drugbank.com/drugs/DB12970InvestigationalLevoglucose has been used in trials studying the diagnostic of Bowel Cleansing Prior to Colonoscopy.
Categories: Compounds used in a research, industrial, or household settingChlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalChlorotoxin I-131 is investigated in clinical trials for treating brain cancer. … The selective effects of Chlorotoxin I-131 are regulated by its action on MMP2 receptors.
Categories: Complex MixturesOxyphenonium
go.drugbank.com/drugs/DB00219ApprovedIt is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem]
Allisartan isoproxil
go.drugbank.com/drugs/DB18880InvestigationalAllisartan isoproxil is under investigation in clinical trial NCT03264352 (Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes).
Categories: Agents Acting on the Renin-Angiotensin SystemCMC 001
go.drugbank.com/drugs/DB05353InvestigationalCMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
ATL1101
go.drugbank.com/drugs/DB05023ExperimentalATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.
Dengue virus serotype 2
go.drugbank.com/drugs/DB22665Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]